Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
4Life Patents LLC has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners and 2 distinct art units. This indicates that the current workload is spread across different personnel and technical divisions at the patent office.
The busiest examiner, BOECKELMAN, JACOB A, is currently handling 1 busiest examiner pending office action. This represents a portion of the total pending actions for the portfolio.
Practitioners should note the diversity in the prosecution environment, as 2 distinct examiners and 2 distinct art units are involved for only 2 pending office actions. This requires tailored approaches for each matter. The focus on Biotechnology & Pharmaceuticals suggests a need for specialized expertise, even with a volume of 2 pending actions. The presence of 2 distinct art units means that the legal team must address the specific examination standards of multiple groups.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOECKELMAN, JACOB A | 1 | 35.2% | +45.6% |
| REYNOLDS, FRED H | 1 | 33.0% | +39.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19260073 | PLANT-DERIVED COMPOSITIONS THAT MODULATE CELLULAR IMMUNITY | BOECKELMAN, JACOB A | 22d |
| 14698698 | COMBINED PROTEIN SUPPLEMENTS | REYNOLDS, FRED H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19260073 | PLANT-DERIVED COMPOSITIONS THAT MODULATE CELLULAR IMMUNITY | BOECKELMAN, JACOB A | 22d |
| 14698698 | COMBINED PROTEIN SUPPLEMENTS | REYNOLDS, FRED H | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19260073 | PLANT-DERIVED COMPOSITIONS THAT MODULATE CELLULAR IMMUNITY | BOECKELMAN, JACOB A | 1655 | §101§103§112 | Non-Final OA | 22d | Pending | Jul 03, 2025 |
| 14698698 | COMBINED PROTEIN SUPPLEMENTS | REYNOLDS, FRED H | 1658 | §103§112 | Final Rejection | — | Pending | Apr 28, 2015 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial